KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer
(NSCLC). It was previously thought to be an" undruggable" target due to the lack of deep …

Lung cancer is the most frequent cancer with an aggressive clinical course and high
mortality rates. Most cases are diagnosed at advanced stages when treatment options are …

Immune checkpoint inhibitors against PD-1/PD-L1 yield improved survival rates of KRAS-
mutant NSCLC patients, who conferred a poor prognosis without effective targeted therapy …

KRAS mutations are the most frequent gain-of-function alterations in patients with lung
adenocarcinoma (LADC) in the Western world. Although they have been identified decades …

Background Although immune checkpoint inhibitors (ICIs) against programmed cell death
protein 1 (PD‐1) and its ligand PD‐L1 have demonstrated potency towards treating patients …

The immune checkpoints are regulatory molecules that maintain immune homeostasis in
physiological conditions. By sending T cells a series of co-stimulatory or co-inhibitory signals …

The efficacy of checkpoint immunotherapy to non-small cell lung cancer (NSCLC) largely
depends on the tumor microenvironment (TME). Here, we demonstrate that CCL7 facilitates …

Simple Summary Rat sarcoma virus (RAS) GTP-ase proteins represent a key element in
cellular proliferation, growth, and differentiation. Three different isoforms of RAS proteins …

Rat sarcoma (RAS) is the most frequently mutated oncogene in human cancer, with Kirsten
rat sarcoma (KRAS) being the most commonly mutated RAS isoform. Overall, KRAS …

Simple Summary Despite an initial response to therapy, many lung cancer patients
inevitably develop resistance to therapy leading to decreased duration of response and …